Literature DB >> 4698978

Clindamycin dose-bioavailability relationships.

C M Metzler, R DeHaan, D Schellenberg, W D Vandenbosch.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1973        PMID: 4698978     DOI: 10.1002/jps.2600620410

Source DB:  PubMed          Journal:  J Pharm Sci        ISSN: 0022-3549            Impact factor:   3.534


× No keyword cloud information.
  6 in total

1.  The effect of cirrhosis on the disposition and elimination of clindamycin.

Authors:  G R Avant; S Schenker; R H Alford
Journal:  Am J Dig Dis       Date:  1975-03

2.  Variation in postantibiotic effect of clindamycin against clinical isolates of Staphylococcus aureus and implications for dosing of patients with osteomyelitis.

Authors:  I B Xue; P G Davey; G Phillips
Journal:  Antimicrob Agents Chemother       Date:  1996-06       Impact factor: 5.191

3.  Parenteral and oral clindamycin therapy in surgical infections: a preliminary report.

Authors:  H T Edmondson
Journal:  Ann Surg       Date:  1973-11       Impact factor: 12.969

4.  Comparative study of bioavailabilities and pharmacokinetics of clindamycin in healthy volunteers and patients with AIDS.

Authors:  G Gatti; J Flaherty; J Bubp; J White; M Borin; J Gambertoglio
Journal:  Antimicrob Agents Chemother       Date:  1993-05       Impact factor: 5.191

5.  New methods for quantification of amoxicillin and clindamycin in human plasma using HPLC with UV detection.

Authors:  Eva Greibe; Claus Ernst Moser; Niels Eske Bruun; Elke Hoffmann-Lücke
Journal:  J Antimicrob Chemother       Date:  2022-08-25       Impact factor: 5.758

6.  Pharmacokinetics and pharmacodynamics of fosmidomycin monotherapy and combination therapy with clindamycin in the treatment of multidrug resistant falciparum malaria.

Authors:  Kesara Na-Bangchang; Ronnatrai Ruengweerayut; Juntra Karbwang; Anurak Chauemung; David Hutchinson
Journal:  Malar J       Date:  2007-05-25       Impact factor: 2.979

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.